SEC Filing Summary: CopyTele, Inc. (10-Q)
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended July 31, 1996, for CopyTele, Inc. (Note: The request metadata listed "Anixa Biosciences," but the filing text explicitly identifies the registrant as CopyTele, Inc.). The company is classified as a Development Stage Enterprise incorporated in November 1982. It has generated no revenue since inception. Its primary activities involve developing flat panel telecommunications technology (specifically the "MAGICOM" product) and managing a 55% interest in a joint venture in Shanghai, China (Shanghai CopyTele Electronics Co., Ltd.).
Key Financial Metrics
| Metric | Nine Months Ended July 31, 1996 | Nine Months Ended July 31, 1995 | Inception through July 31, 1996 |
|---|---|---|---|
| Revenue (Sales) | $0 | $0 | $0 |
| Net Loss | ($3,446,017) | ($2,074,941) | ($26,760,987) |
| Net Loss Per Share | ($0.06) | ($0.04) | ($0.60) |
| Operating Expenses | $3,901,799 | $2,314,749 | $29,882,241 |
| Research & Development | ~$2,450,000 | ~$1,513,000 | ~$19,335,000 |
| Interest Income | $455,782 | $239,808 | $3,121,254 |
| Cash and Equivalents (Ending) | $21,444,593 | $8,720,050 | $21,444,593 |
| Net Cash Used in Operating Activities | ($3,037,813) | ($1,968,580) | ($25,627,436) |
| Net Cash Provided by Financing Activities | $16,656,899 | $4,845,236 | $49,408,577 |
| Debt | None reported | None reported | None reported |
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss for the nine months ended July 31, 1996, increased by approximately $1.37 million compared to the same period in 1995. This was driven by higher selling, general, and administrative expenses.
- Expense Drivers: Increases in expenses were attributed to engineering supplies, professional fees (specifically patent applications), initial marketing costs (opening a marketing office, PR, advertising), and increased personnel and facility costs.
- Joint Venture Loss: The financial results include the company's pro-rata share of losses from its Shanghai joint venture.
- Capital Infusion: Cash balances more than doubled from the prior year period due to significant proceeds from the exercise of stock options and warrants ($16.66 million in financing cash flow for the nine-month period).
- Stock Split: A two-for-one stock split was effected on June 17, 1996. Historical share data has been restated to reflect this.
Guidance, Outlook, and Risks
- Revenue Outlook: Management states there is no assurance that marketable products will be produced or sold in commercial quantities. The company has no revenues to support operations.
- Liquidity: The company believes it has sufficient funds through fiscal 1999 to maintain development efforts and make anticipated capital contributions to a second joint venture, assuming continued salary waivers by senior executives.
- Capital Requirements: The Shanghai joint venture may require up to $25 million in capitalization. A second joint venture may require up to $10 million. The company anticipates seeking additional funding to meet these needs and to satisfy NASD listing requirements (minimum $4 million in net tangible assets).
- Risks: Key risks include the inability to generate future revenues, obsolescence of technology, and the uncertainty of obtaining necessary capital on favorable terms. The company is also subject to the implementation of SFAS No. 123 regarding stock-based compensation.
- Management Commentary: The company is producing production-ready prototypes of the MAGICOM product. Senior management (Chairman, President, and others) continue to waive salary and pension benefits.
Investor Verification Checklist
- Company Identity: Verify that the filing is for CopyTele, Inc., not Anixa Biosciences (as indicated in the request metadata).
- Revenue Generation: Confirm the company remains in the development stage with zero revenue and assess the timeline for commercial product launch.
- Cash Burn Rate: Monitor the rate of cash consumption against the $21.4 million cash balance to validate the "funds through 1999" claim.
- Joint Venture Status: Review the financial health and progress of the Shanghai CopyTele joint venture, which is currently operating at a loss.
- Dilution Risk: Note the significant number of outstanding options and warrants (approx. 9.4 million options and 484k warrants) and the history of financing via option exercises.
- Executive Compensation: Verify the continuation of salary waivers by key executives, as the liquidity projection depends on this assumption.